 Home > Active Ingredient News > Antitumor Therapy > J Urol: The effect of muscle reduction obesity on the prognosis of patients with urinary system cancer

J Urol: The effect of muscle reduction obesity on the prognosis of patients with urinary system cancer

 Last Update: 2021-06-01
 Source: Internet
 Author: User

Tags

ark all dyes

impact protein

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Sarcopenia is a syndrome caused by a continuous decrease in skeletal muscle mass, strength and function.

Muscle-reducing obesity (SO) is a mixed body state of two diseases.

Previous studies have shown that sarcopenia may predict the poor prognosis of patients with urinary system cancer.

Recently published an article on " J Urol " " Sarcopenic Obesity and Its Prognostic Impact on Urologic Cancers: A Systematic Review ", which systematically reviewed the effects of sarcopenic obesity on renal cell carcinoma, urothelial cancer and prostate The prevalence and prognosis of cancer patients.

J Urol J Urol Sarcopenic Obesity and Its Prognostic Impact on Urologic Cancers: A Systematic Review Sarcopenic Obesity and Its Prognostic Impact on Urologic Cancers: A Systematic Review

Researchers searched Embase, PubMed/MEDLINE and Scopus databases to find related articles published between January 2010 and February 2021.

A conceptual model describing the dynamics of fat gain and loss

Fifteen studies were included with a total of 3866 patients.

Ten studies that evaluated survival prognosis showed that the association between sarcopenic obesity and survival was mixed.

The average incidence of sarcopenia obesity in urinary system cancer patients is 27%

All in all, there is a large heterogeneity in the definition of muscle reduction obesity in the previous literature, and the current relevant data are limited.

Original source:

Stangl-Kremser J,Mari A,Lai LY et al.

org/10.
1097/JU.
0000000000001873" target="_blank" rel="noopener">Sarcopenic Obesity and Its Prognostic Impact on Urologic Cancers: A Systematic Review

in this message

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Gefitinib

CAS No.: 184475-35-2

Pharmacy Grade

$1/MT FOB

High quality Sunitinib CAS NO 557795-19-4 Orange solid powder 99% API for antitumor

CAS No.: 557795-19-4

Pharmacy Grade

$4.1-4.2/G FOB

Epirubicin

CAS No.: 56420-45-2

$1/KG EXW

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

announcements today(81)

80 20 company(94)

united states logo(227)

single use technology(195)

healthy food name(42)

ups united states(221)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.